Last updated: July 16, 2026
How did ORTHO-NOVUM 10-21 perform financially and what drives revenue over time?
Answer: No complete, verifiable set of public financials exists in the provided materials to reconstruct ORTHO-NOVUM 10-21’s revenue trajectory with patent-level or product-level precision.
What typically drives sales for an oral contraceptive like ORTHO-NOVUM 10-21?
Revenue for combined oral contraceptives (COCs) depends on a mix of: formulary position, generic penetration rate, payer incentives, channel inventory turns, and persistence/continuation behavior. For older COCs, financial trajectories usually split into two phases:
- Pre-generic erosion: branded pricing supported by exclusivity and channel contracting.
- Post-generic entry: sales compress to remaining brand share where generics face (a) formulary barriers, (b) patient preference, or (c) specific dosing interchange restrictions in practice.
What “market dynamics” usually matter most for COCs?
Key variables with direct financial impact:
- Formulary placement (PBM preference, step edits, prior authorization).
- Generic mix shift driven by WAC-to-NET pricing differentials.
- Switching friction (patient tolerance to formulation change; prescriber habit).
- Manufacturing supply and short-cycle disruptions.
- Regulatory or labeling updates affecting interchangeability or patient suitability.
What is the Orange Book status of ORTHO-NOVUM 10-21 and when does exclusivity end?
Answer: No Orange Book entry, listed patents, or FDA exclusivity dates are available in the provided materials to determine ORTHO-NOVUM 10-21’s current status or exclusivity end dates.
What you need for a correct Orange Book assessment (not present here)
A complete status read requires:
- drug product (proprietary name and strength)
- active ingredient mapping (including salts/esters)
- NDA reference or cross-reference
- listed patents by submission number and expiration dates
- exclusivity codes (3-year, 5-year, 12-year, orphan, pediatric where applicable)
Without those inputs, any “timeline” would be non-actionable.
When do generics typically enter ORTHO-NOVUM 10-21 and what generic entry risks exist?
Answer: The provided materials contain no FDA competitive-entry history (ANDA filings, approvals), so the timing and likelihood of generic entry for ORTHO-NOVUM 10-21 cannot be stated accurately.
What determines generic launch risk for COCs?
Generic entry is driven by:
- patent expiration and any patent “thicket” around formulation, method-of-use, or manufacturing
- whether an ANDA applicant must navigate Paragraph IV litigation or settlement
- whether the brand maintains a stable supply and contracted pricing to retain share
- whether multiple strengths are covered under the same exclusivity/patent set
What patent estate protects ORTHO-NOVUM 10-21 and how strong is it?
Answer: No patent estate data (listed Orange Book patents, unlisted patents, or court dockets) is provided to enumerate claims, expirations, or enforceability for ORTHO-NOVUM 10-21.
Patent estate patterns for older oral contraceptives
For COCs, the most common IP buckets are:
- composition/formulation patents (pill formulation, dosage regimen)
- process/manufacturing patents (granulation, coating, dissolution targets)
- method-of-use patents (less common for older COCs unless tied to specific dosing algorithms)
- polymorph/crystal form or stability-related patents (usually more common in single-API drugs than classic COCs)
Without the actual listed patents and assignees, “strength” cannot be assessed.
Which companies compete against ORTHO-NOVUM 10-21 and how does competitive intensity affect margin?
Answer: No competitor list, market share data, or supplier roster is included in the provided materials.
How competitive intensity typically affects COC economics
Once generics enter:
- brand gross margin erodes from price matching and discounts
- net price declines accelerate due to PBM preferencing
- the opportunity shifts to limited continued brand share and patient-specific switching
A defensible competitive assessment requires: major NDA/ANDA holders, package-level NDC availability, and payer formulary mapping, none of which are present.
What patent litigation affects ORTHO-NOVUM 10-21 and how do settlements change entry timing?
Answer: No litigation dockets, settlement terms, or Paragraph IV claims are provided for ORTHO-NOVUM 10-21.
What to check in real-world ANDA litigation for COCs
A correct litigation-impact read requires:
- court jurisdiction and filing year
- asserted patents and claim constructions
- settlement agreement date, effective dates, and “at-risk” carve-outs
- any 180-day exclusivity awards or forfeitures
No such facts are available here.
How does ORTHO-NOVUM 10-21 compare with other oral contraceptives on lifecycle and pricing pressure?
Answer: No comparative dataset (launch/expiry dates, branded price, generic substitution speed, or utilization trends) is provided in the materials.
What a proper comparison would include
- time since last exclusivity expiry
- number of generic competitors at 12, 24, and 36 months post-entry
- average net price trends by channel
- total prescription trajectory and persistence by strength
What is the FDA regulatory history and does it affect market dynamics?
Answer: No FDA history (approval dates, labeling changes, REMS, safety communications, or interchangeability notes) is included in the provided materials.
Typical regulatory factors for COCs that can shift utilization
- label safety updates that trigger prescriber behavior changes
- formulation changes that affect patient tolerance
- generic interchangeability practicalities in pharmacy workflows
What are the revenue exposure scenarios for ORTHO-NOVUM 10-21 under different entry/exit paths?
Answer: A revenue exposure model cannot be built from the provided materials because it requires at least one of:
- historical revenue by product/strength
- prescription volume and price per script
- FDA/Orange Book events with dated timelines tied to revenue
Scenario framework (method only; no product inputs)
- Base case: stable brand share after first generic entry, slow erosion.
- Down case: rapid PBM preferencing and multi-ANDA entry causing steep net price drop.
- Up case: limited supply interruptions for generics or continued brand preference by patients/payers.
Key Takeaways
- ORTHO-NOVUM 10-21’s market dynamics and financial trajectory cannot be determined from the information provided.
- A reliable analysis requires Orange Book status (listed patents, expirations, exclusivity) plus FDA competitive entry and any Paragraph IV litigation or settlements; none are present.
- Without verifiable financial or regulatory timeline data, any revenue trajectory, exclusivity end date, or generic entry timing would be speculative.
FAQs
- What public sources normally show NDAs, ORANGE BOOK patents, and exclusivity for branded COCs?
- How do PBM formulary decisions typically change net pricing for older branded oral contraceptives after generic entry?
- What signals indicate whether an ANDA for a COC is likely to launch quickly or be delayed by patent litigation?
- How can differences in dosing regimens across COC strengths affect generic substitution and persistence?
- What does a complete product-level “market dynamics” model require for prescription volume, price, and share by strength?
References
- (No sources were provided in the prompt.)
